Guangdong Development Capital
VC Fund
Guangdong Development Capital is an investment firm.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Guangdong Development Capital invests in
Stages Guangdong Development Capital invests in
Countries Guangdong Development Capital invests in
Investment Focus
Industry
- Biotechnology 2 (22%)
- Laser 1 (11%)
- Medical 1 (11%)
- Aerospace 1 (11%)
- Health Care 1 (11%)
Stage
- Series C 2 (22%)
- Series E 2 (22%)
- Series A 1 (11%)
- Series B 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Chuangzhi Lianheng
|
Chuangzhi Lianheng has completely self-developed 5G wireless communication core technology and offers a range of independent products such as 5G base stations and low-orbit satellite communication loads. It is a maker of equipment that specializes in 5G communications and low-orbit satellite communication services. The company's primarybusiness orientation is satellite Internet, and it is a pioneer in the field of low-orbit satellite broadband evolution system communications. | Series A / Jul 31, 2026 | |
Cascade
|
Cascade produces novel medications that target nuclear receptors for treating metabolic disorders and inflammation. | $46.9M / Series D / Jun 10, 2026 | |
New Radiomedicine Technology
|
Chengdu New Radiomedicine Technology Co.,Ltd. is a Chinese medical isotopes provider. Our business covers research, manufacture and sales for medical isotopes and products. We provide services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting.In April 2016, the company was founded bythree co-founders experienced in radionuclides research and development. Jihui Qian, former President of Nuclear Power Institute of China (NPIC), former Deputy Director-General of International Atomic Energy Agency (IAEA); Maoliang Li, former Director of Chengdu Isotopes Institute of NPIC; and Jiming Cai, former Vice President of Sichuan Institute of Atomic Energy.The company is located in Western Airport Development District, Shuangliu, Chengdu, with an area of 71 Are, registered capital of 32.83 million CNY, and total investment of 300 million CNY. The project is listed as "Annual Key Investment Projects of Sichuan Province and Chengdu City in 2017, 2018 and 2019". At present, the company has over 80 employees, with more than 60 R&D specialists, including 1 academician of Chinese Academy of Engineering, 2 experts of Thousand Talent Project, 2 academic and technical leaders from Sichuan province, 10 researchers (associate researchers), and more than 20 people with middle or senior titles. Among them, there are 6 PhDs and over 30 graduates. The proportion of R&D staff has reached 70%, making CNRT the most innovative technology enterprise in the radiopharmaceutical industry in China. | $145.4M / Series E / Apr 03, 2026 | |
Yunyao Aerospace Technology
|
Yunyao Aerospace Technology is a comprehensive service platform that integrates "Global Space Weather Data Production"+"Space Weather Data. The company is based in Tianjin, China. | $72.6M / Series B / Apr 02, 2026 | |
Laser Link
|
Laser Link is a laser communication company that focuses on the development of precision optical-mechanical products for commercial aircraft. | $72.7M / Series C / Mar 10, 2026 | |
Aurora Starcom
|
Aurora Starcom is a national high-tech company specialising in the research and development of space laser communication technology. | $43.2M / Series A / Feb 06, 2026 | |
Sinovent
|
Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation. Sinovent is centered around global standard excellence through its advanced biotechnology platform, decades of management experience, as well as financial support. Sinovent uniquely combines its expertise in science, management and finance, to develop and promoteadvanced treatment methods to solve worldwide healthcare problems. Currently, the company has 12 products in development, primarily in oncology, auto-immune diseases, and infectious diseases. | $97.3M / Series E / Feb 20, 2024 | |
Jingwei Slewing Bearing
|
Jingwei Slewing Bearing is a transmission equipment company that specializes in the development and manufacturing of slewing bearings. | $14.1M / Series C / Dec 31, 2023 | |
Boshi Hi-tech
|
Boshi Hi-tech develops lithium-ion battery cathode materials for research, production and sales of lithium-ion battery cathode materials. | Series A / Sep 01, 2021 |
Co-Investors
Guoxin Investment
2 deals together
Pudong Chuangtou
2 deals together
ABC Capital
1 deal together
Apricot Capital
1 deal together
CAS Investment Management
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Guangdong Development Capital invest in?
Guangdong Development Capital invests primarily in Biotechnology, Laser and Medical startups, most often at Series C and Series E stage. Most of the 9 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Guangdong Development Capital last invest?
The most recent investment recorded for Guangdong Development Capital closed in Jul 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
